keynote048: first line pembrolizumab for r/m hnscc
Published 5 years ago • 81 plays • Length 5:24Download video MP4
Download video MP3
Similar videos
-
6:46
first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma
-
3:08
keynote-048: pembrolizumab monotherapy for frontline r/m hnscc
-
7:56
keynote-048: progression post next line for r/m hnscc
-
7:03
lba8_pr - keynote-048: phase 3 study of first-line pembrolizumab in r/m hnscc
-
7:13
first-line pembrolizumab plus chemotherapy for patients with advanced squamous nsclc: 3-year fol...
-
1:48
post hoc keynote-040 analysis: pembrolizumab for hnscc produces lasting immune effect
-
5:34
pembrolizumab for recurrent hnscc
-
1:58
dr. rischin on keynote-048 results in head and neck squamous cell carcinoma
-
2:45
final keynote-048 results with frontline pembrolizumab in recurrent/metastatic hnscc
-
4:42
pembrolizumab for recurrent head and neck squamous cell carcinomas (hnscc)
-
4:46
preliminary results from keynote-055: pembrolizumab in hnscc
-
11:47
pembrolizumab in hnscc
-
1:13
keynote-b84: pepinemab pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma
-
6:17
pembrolizumab for head and neck cancer
-
7:03
pembrolizumab for frontline head and neck cancer: keynote-048 results
-
2:26
sd-101 plus pembrolizumab for hnscc
-
2:46
keynote-427 updates: first-line pembrolizumab monotherapy in patients with advanced clear cell r...
-
6:38
pembrolizumab with chemotherapy as first line for metastatic cervical cancer
-
3:44
pembrolizumab plus chemo shows prolonged os and pfs improvement vs chemo for squamous nsclc